Lupin has informed that it has enclosed a Press Release as regards launch of Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg for which US FDA approval was received earlier. This is considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015.
The above information is a part of company’s filings submitted to BSE.